Without the additional adjustment the adjusted odds ratios for ≤ 2 or > 2 prescriptions were 0.97 (95% CI: 0.77, 1.2) and 0.83 (95% CI: 0.61, 1.1), respectively.
With the repeat analysis of the risk of dementia with ARB exposure in the initial 12 months following the index date with the additional adjustment for stroke, the adjusted hazard ratio for dementia was 0.61 (95% CI 0.51 0.73).
Further adjustment for caloric intake had little impact on the age-, sex-, and percent body fat adjusted associations between PA and fasting glucose, 2-h glucose, fasting insulin, 2-h insulin, AIRg, SI, and DI; the additional adjustment resulted in <10% change in the corresponding regression coefficients, with adjusted P values of 0.098, 0.017, 0.0003, 0.016, 0.21, 0.16, and 0.019, respectively.
In post hoc analyses, the association of cIMT with 4-year decline in g survived the additional adjustment for MHVS (β = −0.13; P = 0.001) as well as addition of stroke, ABI, and NT-proBNP into the model (β = −0.12; P = 0.002).
After the additional adjustment for discontinuation of fenofibrate therapy, efficacy estimates moderately improved to a 15% reduction in cardiovascular events (P = 0.008) and a 16% reduction in CHD events (P = 0.06).
It was found that, as compared to the equilibrated S1 conformation from B-S1 or reconstructed "E-S1" structure (1st or 2nd set of bars from the left), the additional adjustment of residue W1 or D89 orientation tuned to that of S2 did not induce conformational change of S1 Lec domain (RMSD <3.0 Å, 3rd and 6th solid bars).
However, given the direction of the associations, additional adjustment for body mass index or other similar risk factors would, if anything, tend to attenuate the relative risk further.
Due to a small sample size, the multivariable models were only adjusted for the surgery type; additional adjustment would have led to over-adjusted models.
Further adjustment for concurrent DMARD therapy made little difference to the estimate, although additional adjustment for the a priori confounders reduced the estimate to 1.20 (1.15 to 1.25).
The first model was adjusted for sex and age; the second included additional adjustment for education, ethnicity, and co-habitation; and the third also included adjustment for comorbidity.
On the other hand, additional adjustment for saturated fat moderately reduced the association between high-fat dairy and CVD mortality, but remained statistically significant.
